کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2113070 | 1084439 | 2013 | 10 صفحه PDF | دانلود رایگان |

Pancreatic adenocarcinoma is an aggressive disease with a high mortality rate. In this study, we have newly generated a monoclonal antibody (mAb), Pa65-2, which specifically binds to pancreatic cancer cells and tumor blood vessels. The target protein of Pa65-2 is identified as human clathrin heavy chain (CHC). In vitro and In vivo study showed that suppression of CHC either by shRNA or by Pa65-2 inhibited tumor growth and angiogenesis. One of the key functions of CHC was to bind with the hypoxia-inducing factor (HIF)-1α protein, increasing the stability of this protein and facilitating its nuclear translocation, thereby regulating the expression of VEGF. Taken together, our findings indicate that CHC plays a role in the processes of tumorigenesis and angiogenesis. Pa65-2 antibody or CHC shRNA can potentially be used for pancreatic cancer therapy.
► CHC promotes tumor growth, invasion and angiogenesis in vitro and in vivo.
► CHC interacts with and stabilizes HIF-1α, and leads to an increased production of VEGF.
► Pa65-2 antibody can potentially be used to inhibit tumor angiogenesis and growth.
Journal: Cancer Letters - Volume 331, Issue 1, 30 April 2013, Pages 58–67